Page 307 - Read Online

Page 12 of 18 Qureshy et al. J Cancer Metastasis Treat 2020;6:27 I http://dx.doi.org/10.20517/2394-4722.2020.58

DECLARATIONS
Authors’ contributions
Drafted and edited manuscript, figures, and tables: Qureshy Z, Johnson DE, Grandis JR

Availability of data and materials
Not applicable.

Financial support and sponsorship
This work was supported by NIH (R35CA231998) (to Grandis JR), (R01DE028289) (to Johnson DE,
Grandis JR); and a Yearlong Research Fellowship awarded by the University of California San Francisco
School of Medicine (to Qureshy Z).

Conflicts of interest
Johnson DE and Grandis JR are co-inventors of cyclic STAT3 decoy and have financial interests in STAT3
Therapeutics. STAT3 Therapeutics holds an interest in cyclic STAT3 decoy. Qureshy Z declared that there
are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Thomas SJ, Snowden JA, Zeidler MP, Danson SJ. The role of JAK/STAT jnsignalling in the pathogenesis, prognosis and treatment of
solid tumours. Br J Cancer 2015;113:365-71.
2. O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in Immunity, Immunodeficiency, and Cancer. N Engl J Med 2013;368:161-70.
3. O’Sullivan JM, Harrison CN. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplas ms. Mol Cell Endocrinol
2017;451:71-9.
4. Khanna P, Lee JS, Sereemaspun A, Lee H, Baeg GH. GRAMD1B regulates cell migration in breast cancer cells through JAK/STAT and
Akt signaling. Sci Rep 2018;8:9511.
5. Haque I, Ghosh A, Acup S, Banerjee S, Dhar K, et al. Leptin-induced ER-α-positive breast cancer cell viability and migration is mediated
by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway. BMC Cancer 2018;18:99.
6. Lokau J, Schoeder V, Haybaeck J, Garbers C. Jak-Stat signaling induced by interleukin-6 family cytokines in hepatocellular carcinoma.
Cancers (Basel) 2019;11:1704.
7. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, et al. Constitutive activation of stat3 signaling abrogates apoptosis in
squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A 2000;97:4227-32.
8. Wu CS, Wei KL, Chou JL, Lu CK, Hsieh CC, et al. Aberrant JAK/STAT signaling suppresses TFF1 and TFF2 through epigenetic
silencing of GATA6 in gastric cancer. Int J Mol Sci 2016;17:1467.
9. Shang AQ, Wu J, Bi F, Zhang YJ, Xu LR, et al. Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and
clinicopathological features and prognosis of ovarian cancer. Cancer Biol Ther 2017;18:314-22.
10. Nishi M, Batsaikhan BE, Yoshikawa K, Higashijima J, Tokunaga T, et al. High STAT4 expression indicates better disease-free survival in
patients with gastric cancer. Anticancer Res 2017;37:6723-9.
11. Nikitakis N, Siavash H, Sauk J. Targeting the STAT pathway in head and neck cancer: recent advances and future prospects. Curr Cancer
Drug Targets 2005;4:637-51.
12. Khanna P, Chua PJ, Bay BH, Baeg GH. The JAK/STAT signaling cascade in gastric carcinoma (Review). Int J Oncol 2015;47:1617-26.
13. Tabassum S, Abbasi R, Ahmad N, Farooqi AA. Targeting of JAK-STAT signaling in breast cancer: therapeutic strategies to overcome
drug resistance. Adv Exp Med Biol 2019;1152:271-81.
14. Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene 2013;32:2601-13.
15. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl